March 26, 2014
New York, New York
The Alliance for Regenerative Medicine in partnership with Maxim Group and Piper Jaffray will host a one-day, high impact program providing institutional, strategic and venture investors with unique insight into the financing hypothesis for regenerative medicine and advanced therapies-based treatment and tools. The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how regen med could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.